Literature DB >> 11751186

Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy.

M F Phillips1, R C Quinlivan, R H Edwards, P M Calverley.   

Abstract

Duchenne muscular dystrophy (DMD) causes a progressive impairment of muscle function leading to hypercapnic respiratory failure. Most studies of respiratory function in DMD have been cross-sectional rather than longitudinal, and these data have not been related to survival. We retrospectively studied 58 patients with DMD with at least 2 yr of follow-up spirometry and known vital status. Spirometry was abnormal at entry: median FEV(1) 1.60 L (range 0.4 to 2.6 L), FVC 1.65 L (range 0.45 to 2.75 L), FVC 64% predicted (range 29 to 97%). Individual rates of change of vital capacity varied, with a median annual change of -0.18 L (range 0.04 to -0.74 L), -8.0% predicted FVC (range 2 to -39%). During the study 37 patients died; the median age of death, calculated by Kaplan-Meier analysis, was 21.5 yr (range 15 to 28.5 yr). The age when vital capacity fell below 1 L was a strong marker of subsequent mortality (5-yr survival 8%). The maximal vital capacity recorded and its rate of decline (however expressed) predicted survival time. Repeated spirometric measurement provides a simple and relatively powerful means of assessing disease progression in these patients and should be considered when planning treatment trials.

Entities:  

Mesh:

Year:  2001        PMID: 11751186     DOI: 10.1164/ajrccm.164.12.2103052

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

1.  Cardiac and pulmonary function variability in Duchenne/Becker muscular dystrophy: an initial report.

Authors:  David J Birnkrant; Mahi Lakshmi Ashwath; Garey H Noritz; Michelle C Merrill; Tushar A Shah; Carol A Crowe; Robert C Bahler
Journal:  J Child Neurol       Date:  2010-05-25       Impact factor: 1.987

2.  Pulmonary and upper limbs function in children with early stage Duchenne muscular dystrophy compared to their healthy peers.

Authors:  Numan Bulut; Güllü Aydın; İpek Alemdaroğlu-Gürbüz; Ayşe Karaduman; Öznur Yılmaz
Journal:  Braz J Phys Ther       Date:  2020-06-05       Impact factor: 3.377

3.  Inspiratory pressure-generating capacity is preserved during ventilatory and non-ventilatory behaviours in young dystrophic mdx mice despite profound diaphragm muscle weakness.

Authors:  David P Burns; Kevin H Murphy; Eric F Lucking; Ken D O'Halloran
Journal:  J Physiol       Date:  2019-01-13       Impact factor: 5.182

4.  Short-term effect of volume recruitment-derecruitment manoeuvre on chest-wall motion in Duchenne muscular dystrophy.

Authors:  Henri Meric; Line Falaize; Didier Pradon; Matthieu Lacombe; Michel Petitjean; David Orlikowski; Hélène Prigent; Frédéric Lofaso
Journal:  Chron Respir Dis       Date:  2017-02-24       Impact factor: 2.444

5.  Reduced serum myostatin concentrations associated with genetic muscle disease progression.

Authors:  Peter M Burch; Oksana Pogoryelova; Joe Palandra; Richard Goldstein; Donald Bennett; Lori Fitz; Michela Guglieri; Chiara Marini Bettolo; Volker Straub; Teresinha Evangelista; Hendrik Neubert; Hanns Lochmüller; Carl Morris
Journal:  J Neurol       Date:  2017-01-10       Impact factor: 4.849

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

7.  Chronic hypoxia impairs muscle function in the Drosophila model of Duchenne's muscular dystrophy (DMD).

Authors:  Matias Mosqueira; Gabriel Willmann; Hannele Ruohola-Baker; Tejvir S Khurana
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

8.  Respiratory dysfunction in unsedated dogs with golden retriever muscular dystrophy.

Authors:  Justin C DeVanna; Joe N Kornegay; Daniel J Bogan; Janet R Bogan; Jennifer L Dow; Eleanor C Hawkins
Journal:  Neuromuscul Disord       Date:  2013-10-24       Impact factor: 4.296

Review 9.  Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.

Authors:  Alessandra Govoni; Francesca Magri; Simona Brajkovic; Chiara Zanetta; Irene Faravelli; Stefania Corti; Nereo Bresolin; Giacomo P Comi
Journal:  Cell Mol Life Sci       Date:  2013-06-18       Impact factor: 9.261

10.  Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy.

Authors:  Anne M Connolly; Elizabeth C Malkus; Jerry R Mendell; Kevin M Flanigan; J Philip Miller; Jeanine R Schierbecker; Catherine A Siener; Paul T Golumbek; Craig M Zaidman; Craig M Mcdonald; Linda Johnson; Alina Nicorici; Peter I Karachunski; John W Day; Jason M Kelecic; Linda P Lowes; Lindsay N Alfano; Basil T Darras; Peter B Kang; Janet Quigley; Amy E Pasternak; Julaine M Florence
Journal:  Muscle Nerve       Date:  2015-02-11       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.